Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status

Thasni Karedath Abdul Azis, Gopakumaran Rojini, S. Nair Rakesh, Thankappan Ratheeshkumar, Mani Shankar Babu, Gopala Srinivas, Asoke Banerji, Priya Srinivas

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

It has been reported that Breast Cancer Susceptibility gene-1 & 2 (BRCA1 & 2 are potential molecular targets for chemoprevention by isoflavone genistein (4′ 5, 7-trihydroxy isoflavone), in breast and prostate cancer cells. It is also known that BRCA1 has inhibitory activity on estrogen receptor-α and genistein's action on cells is mainly through modulation of estrogen receptor activity. The action of genistein with respect to BRCA1 status in ovarian cancer cells has not been reported so far. Therefore in this study, we analyzed the action of genistein on BRCA1 antisense blocked (AS4) and unblocked (NEO) BG-1 ovarian cancer cells. We found that genistein induced comparable cytotoxic effect in both AS4 and NEO cells, but through different pathways. We found that genistein induces caspase 8 dependent apoptotic pathway in NEO cells. Genistein inhibits estrogen receptor-α and activates BARD1 in BRCA1 blocked cells and induces estrogen receptor-β and FAS in presence of BRCA1. It can be concluded that even though there is no difference in the extent of cell death or apoptosis, the molecular mechanism of action of genistein in inducing apoptosis is different in BRCA1 blocked and unblocked cells. This could partially explain the beneficial effects of genistein in both wild type and mutated BRCA1 estrogen receptor positive tumors.

Original languageEnglish
Pages (from-to)158-164
Number of pages7
JournalEuropean Journal of Pharmacology
Volume588
Issue number2-3
DOIs
Publication statusPublished - 7 Jul 2008
Externally publishedYes

Fingerprint

Genistein
Neoplasm Genes
Ovarian Neoplasms
Apoptosis
Breast Neoplasms
Estrogen Receptors
Isoflavones
Caspase 8
Chemoprevention
Prostatic Neoplasms
Cell Death

Keywords

  • Apoptosis
  • BRCA1
  • Estrogen receptor
  • Genistein
  • Ovarian cancer

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status. / Karedath Abdul Azis, Thasni; Rojini, Gopakumaran; Rakesh, S. Nair; Ratheeshkumar, Thankappan; Babu, Mani Shankar; Srinivas, Gopala; Banerji, Asoke; Srinivas, Priya.

In: European Journal of Pharmacology, Vol. 588, No. 2-3, 07.07.2008, p. 158-164.

Research output: Contribution to journalArticle

Karedath Abdul Azis, Thasni ; Rojini, Gopakumaran ; Rakesh, S. Nair ; Ratheeshkumar, Thankappan ; Babu, Mani Shankar ; Srinivas, Gopala ; Banerji, Asoke ; Srinivas, Priya. / Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status. In: European Journal of Pharmacology. 2008 ; Vol. 588, No. 2-3. pp. 158-164.
@article{712ac558f39e49188a41359d3eb28dc9,
title = "Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status",
abstract = "It has been reported that Breast Cancer Susceptibility gene-1 & 2 (BRCA1 & 2 are potential molecular targets for chemoprevention by isoflavone genistein (4′ 5, 7-trihydroxy isoflavone), in breast and prostate cancer cells. It is also known that BRCA1 has inhibitory activity on estrogen receptor-α and genistein's action on cells is mainly through modulation of estrogen receptor activity. The action of genistein with respect to BRCA1 status in ovarian cancer cells has not been reported so far. Therefore in this study, we analyzed the action of genistein on BRCA1 antisense blocked (AS4) and unblocked (NEO) BG-1 ovarian cancer cells. We found that genistein induced comparable cytotoxic effect in both AS4 and NEO cells, but through different pathways. We found that genistein induces caspase 8 dependent apoptotic pathway in NEO cells. Genistein inhibits estrogen receptor-α and activates BARD1 in BRCA1 blocked cells and induces estrogen receptor-β and FAS in presence of BRCA1. It can be concluded that even though there is no difference in the extent of cell death or apoptosis, the molecular mechanism of action of genistein in inducing apoptosis is different in BRCA1 blocked and unblocked cells. This could partially explain the beneficial effects of genistein in both wild type and mutated BRCA1 estrogen receptor positive tumors.",
keywords = "Apoptosis, BRCA1, Estrogen receptor, Genistein, Ovarian cancer",
author = "{Karedath Abdul Azis}, Thasni and Gopakumaran Rojini and Rakesh, {S. Nair} and Thankappan Ratheeshkumar and Babu, {Mani Shankar} and Gopala Srinivas and Asoke Banerji and Priya Srinivas",
year = "2008",
month = "7",
day = "7",
doi = "10.1016/j.ejphar.2008.04.041",
language = "English",
volume = "588",
pages = "158--164",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Genistein induces apoptosis in ovarian cancer cells via different molecular pathways depending on Breast Cancer Susceptibility gene-1 (BRCA1) status

AU - Karedath Abdul Azis, Thasni

AU - Rojini, Gopakumaran

AU - Rakesh, S. Nair

AU - Ratheeshkumar, Thankappan

AU - Babu, Mani Shankar

AU - Srinivas, Gopala

AU - Banerji, Asoke

AU - Srinivas, Priya

PY - 2008/7/7

Y1 - 2008/7/7

N2 - It has been reported that Breast Cancer Susceptibility gene-1 & 2 (BRCA1 & 2 are potential molecular targets for chemoprevention by isoflavone genistein (4′ 5, 7-trihydroxy isoflavone), in breast and prostate cancer cells. It is also known that BRCA1 has inhibitory activity on estrogen receptor-α and genistein's action on cells is mainly through modulation of estrogen receptor activity. The action of genistein with respect to BRCA1 status in ovarian cancer cells has not been reported so far. Therefore in this study, we analyzed the action of genistein on BRCA1 antisense blocked (AS4) and unblocked (NEO) BG-1 ovarian cancer cells. We found that genistein induced comparable cytotoxic effect in both AS4 and NEO cells, but through different pathways. We found that genistein induces caspase 8 dependent apoptotic pathway in NEO cells. Genistein inhibits estrogen receptor-α and activates BARD1 in BRCA1 blocked cells and induces estrogen receptor-β and FAS in presence of BRCA1. It can be concluded that even though there is no difference in the extent of cell death or apoptosis, the molecular mechanism of action of genistein in inducing apoptosis is different in BRCA1 blocked and unblocked cells. This could partially explain the beneficial effects of genistein in both wild type and mutated BRCA1 estrogen receptor positive tumors.

AB - It has been reported that Breast Cancer Susceptibility gene-1 & 2 (BRCA1 & 2 are potential molecular targets for chemoprevention by isoflavone genistein (4′ 5, 7-trihydroxy isoflavone), in breast and prostate cancer cells. It is also known that BRCA1 has inhibitory activity on estrogen receptor-α and genistein's action on cells is mainly through modulation of estrogen receptor activity. The action of genistein with respect to BRCA1 status in ovarian cancer cells has not been reported so far. Therefore in this study, we analyzed the action of genistein on BRCA1 antisense blocked (AS4) and unblocked (NEO) BG-1 ovarian cancer cells. We found that genistein induced comparable cytotoxic effect in both AS4 and NEO cells, but through different pathways. We found that genistein induces caspase 8 dependent apoptotic pathway in NEO cells. Genistein inhibits estrogen receptor-α and activates BARD1 in BRCA1 blocked cells and induces estrogen receptor-β and FAS in presence of BRCA1. It can be concluded that even though there is no difference in the extent of cell death or apoptosis, the molecular mechanism of action of genistein in inducing apoptosis is different in BRCA1 blocked and unblocked cells. This could partially explain the beneficial effects of genistein in both wild type and mutated BRCA1 estrogen receptor positive tumors.

KW - Apoptosis

KW - BRCA1

KW - Estrogen receptor

KW - Genistein

KW - Ovarian cancer

UR - http://www.scopus.com/inward/record.url?scp=44949133877&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44949133877&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2008.04.041

DO - 10.1016/j.ejphar.2008.04.041

M3 - Article

VL - 588

SP - 158

EP - 164

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -